The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Experimental Hematology & Oncology
Rasmus Strøm RisbjergTue Wenzel Kragstrup

Abstract

This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.

Citations

Feb 10, 2021·Journal of Biomolecular Structure & Dynamics·Aline de Oliveira AlbuquerqueJoão Hermínio Martins da Silva
Jul 29, 2021·Nature Reviews. Drug Discovery·Ryan J Sullivan, Jeffrey S Weber

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02541565
NCT03259529
NCT03749018
NCT03704714
NCT03719131
NCT03630042
NCT03934814
NCT02677155
NCT03245021
NCT03995147

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved